SynthesisBMC infectious diseases2021
Hepatitis B vaccination coverage in Germany: systematic review.
Synthesis in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Self-reported hepatitis B diagnoses and vaccination history in trans and non-binary communities in Germany, the TASG-study* 2022.BMC public health · 2026Article
- Feasibility of eliminating adult hepatitis B in Guangdong by 2030: A modeling study.Infectious Disease Modelling · 2026Article
- Article
- Hepatitis B vaccination and post-exposure prophylaxis in healthcare workers - a comparative analysis of national and supranational recommendations.GMS hygiene and infection control · 2026Review
- What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based study.Frontiers in oncology · 2025Article
- Use and application of geographical restrictions in systematic reviews with the aim of including studies about Germany: An update of a methodological review.Health information and libraries journal · 2024Review
- Prevalence of vaccine-derived hepatitis B surface antibodies in children and adolescents in Germany: results from a population-based survey, 2014-2017.BMC infectious diseases · 2024Article
- Article
- High hepatitis B vaccination coverage among a cohort of predominantly men who have sex with men in Germany.Human vaccines & immunotherapeutics · 2023Observational
- Evaluation of the effect of enhanced immunization in adults: A cross-sectional study in the southeast city of China.Human vaccines & immunotherapeutics · 2022Article
- Adult Hepatitis B Virus Vaccination Coverage in China from 2011 to 2021: A Systematic Review.Vaccines · 2022Review
- Review
- [Epidemiology of viral hepatitis A to E in Germany].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2022Review
- [Hepatitis B virus infection and vaccine-induced immunity: the role of sociodemographic determinants : Results of the study "German Health Interview and Examination Survey for Adults" (DEGS1, 2008-2011)].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2022Article
- Article
- The Prevalence and Determinants of Viral Hepatitis Among Homeless Individuals in Hamburg.Deutsches Arzteblatt international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite being considered as a low prevalence country for hepatitis B (HBV), some populations in Germany are at higher risk of infection. In the context of the World Health Organization's (WHO) viral hepatitis elimination goals, a valid epidemiological data base is needed to plan and monitor the national response. Prevention strategies include general and targeted HBV vaccination programmes.
objectiveThe aim of this work was to estimate the HBV vaccination coverage (VC) in the general population (GP) and different population groups in Germany from available evidence and to identify current evidence gaps for future research.
methodsWe conducted a systematic review on HBV VC in the general population and populations at high risk of HBV exposure or severe infection in Germany. We included eligible publications (01/01/2017 to 06/06/2020) from databases Embase, Pubmed and Livivo, from a previous scoping review (including data published 01/01/2005-17/03/2017), from the national surveillance system and screened the reference lists of all publications at full text level. Risk of bias was assessed using the Hoy et al. tool.
resultsWe included 68 publications of 67 studies and assigned them to one or more suitable population groups. Twenty-one studies contained data among children/adolescents and three among adults from the GP (VC 65.8-90.5% and 22.9-52.1%, respectively), one among travelers (VC 89.0%), 13 among immunocompromised populations (VC 7.8-89.0%), 16 among populations with occupational risk and 16 with non-occupational risk of HBV exposure (VC 63.6-96.5% and 4.4-84.5%, respectively).
conclusionComprehensive evidence at low risk of bias was identified for children/adolescents. However, 25 years after including HBV in the national immunisation schedule, VC in Germany is still below the 95%-goal defined by WHO. For people at occupational risk of HBV exposure, VC was mostly reported to be over the WHO goal of 80%, but quality of evidence was heterogenous and should be improved. For people at non-occupational risk of HBV exposure, evidence was sparse and of low quality. The low VC highlights the need for future research to plan vaccination programmes targeting these populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.